ArticleDiabetology & metabolic syndrome2025
Synergistic effects of NF-κB1 and inflammatory pathway polymorphisms on hypertension and dyslipidemia susceptibility in type 2 diabetes.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular Mechanisms Associated with Metabolic Dysfunction: Contributions of Nutritional Genomics.Metabolites · 2026Review
- α-Glucosidase Inhibition-Guided Network Pharmacology and Molecular Docking Reveal the Antidiabetic Potential ofInternational journal of molecular sciences · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) patients exhibit a heightened susceptibility to concurrent hypertension (HTN) and dyslipidemia (DYS), conditions that reciprocally exacerbate cardiovascular risks. This study investigated the association between NF-κB1 polymorphism, related inflammatory mediators, and the predisposition to hypertension and dyslipidemia in T2DM patients, along with their correlations with biochemical parameters.
methodsGenotyping of 452 T2DM patients was performed using SNP-scan high-throughput technology. Analyzed polymorphisms encompassed: NF-κB1-rs4648068, upstream transcriptional regulators (TLR2-rs3804099, TLR4-rs2149356, TLR9-rs352140), and downstream inflammatory mediators (IL6-rs1800796, IL6R-rs2228145, IL10-rs1800872, ICAM1-rs5498 and rs3093030). The cohort was stratified into three clinically defined groups: T2DM-only (T2DM group), T2DM with hypertension (T2MH group), and T2DM with comorbid hypertension and dyslipidemia (T2MH-DYS group). The T2MH and T2MH-DYS groups were further subclassified into Grade I-III according to hypertension staging criteria. Plasma biochemical profiles were systematically evaluated to delineate their associations with NF-κB1 pathway genetic variants.
resultsPatients with T2DM complicated by hypertension (T2MH) or hypertension with dyslipidemia (T2MH-DYS) exhibited distinct metabolic and inflammatory profiles. Genetic analyses revealed significant polymorphisms in inflammatory pathway genes (TLR9, TLR2, NF-κB1, IL6R) across subgroups. TLR9 rs352140 CT heterozygotes conferred a 2.8-2.94-fold increased risk of T2MH/T2MH-DYS, while NF-κB1 rs4648068 GG genotype reduced dyslipidemia risk by 64.8% (P = 0.004). Haplotype analysis identified synergistic effects: the TLR9/IL6R/NF-κB1 risk haplotype (G-C-T) increased hypertension risk 3.26-fold (P = 0.00069), and the IL10/TLR4/NF-κB1 protective haplotype (G-T-A) reduced dyslipidemia risk by 82% (P = 0.0063). IL10 rs1800872 TT genotype and TLR4 rs2149356 G allele were linked to dyslipidemia susceptibility in hypertensive diabetics.
conclusionThis study establishes that genetic variants in inflammatory pathways (TLR9, NF-κB1, IL6R) synergistically drive hypertension and dyslipidemia risks in T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.